Valuation: Immuneering Corporation

Market Cap 267M 232M 216M 198M 375M 25.51B 381M 2.55B 1B 12.7B 1B 981M 42.58B P/E 2026 *
-3.71x
P/E 2027 * -3.21x
Enterprise Value 267M 232M 216M 198M 375M 25.51B 381M 2.55B 1B 12.7B 1B 981M 42.58B EV / Sales 2026 *
-
EV / Sales 2027 * 13.7x
Free-Float
86.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day-2.36%
1 week-4.40%
1 month-18.22%
3 months-23.09%
6 months-10.80%
Current year-37.23%
1 week 4.03
Extreme 4.03
4.51
1 month 4.03
Extreme 4.03
5.7
Current year 3.86
Extreme 3.86
8.48
1 year 2.9
Extreme 2.9
10.08
3 years 1
Extreme 1
10.95
5 years 1
Extreme 1
33.99
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 01/02/2008
Director of Finance/CFO 61 16/07/2026
Chief Tech/Sci/R&D Officer - 01/08/2023
Director TitleAgeSince
Chairman 81 01/01/2008
Director/Board Member 44 01/02/2008
Director/Board Member 72 27/04/2021
Date Insider Type Main position Quantity % Market Cap.
7/16/26 A Other

Chief Financial Officer

225,000 0.3478%
7/16/26 A Free

Chief Financial Officer

650,000 1.0047%
2/3/26 A Free

Chief Technology Officer

140,000 0.2168%
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%-4.40%+22.55%-61.18% 267M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.35%-3.85%+34.54%+133.21% 23.41B
Weighted average by Cap. +0.23%-2.96%+30.78%+116.63%

Financials

2026 *2027 *
Net sales - 19.5M 16.95M 15.78M 14.49M 27.36M 1.86B 27.78M 186M 72.99M 927M 73.23M 71.63M 3.11B
Net income -74.87M -65.08M -60.58M -55.62M -105M -7.15B -107M -714M -280M -3.56B -281M -275M -11.93B -87.34M -75.92M -70.67M -64.88M -123M -8.34B -124M -833M -327M -4.15B -328M -321M -13.92B
Net Debt - -
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
55
Date Price Change Volume
31/07/26 $4.130 -2.36% 409,671
30/07/26 $4.230 +4.32% 510,073
29/07/26 $4.055 -4.36% 801,355
28/07/26 $4.240 -2.75% 712,595
27/07/26 $4.360 +0.93% 459,902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.130USD
Average target price
18.86USD
Spread / Average Target
+356.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMRX Stock